Get started
Author

L. Elit

Observed names: Elit, Lorraine, L Elit, L M Elit, L.M. Elit, LM Elit, Lorraine Elit, Lorraine M. Elit, Lorraine Margaret Elit
Institution: Kijabe Hospital
Observed institutions: Western University, St. Michael's Hospital, Dalhousie University, Sunnybrook Health Science Centre, University of British Columbia, University of Ottawa, University of Alberta, University of Toronto, International Breast Cancer Research Foundation, Loma Linda University, Juravinski Cancer Centre, Canadian Partnership Against Cancer, Ottawa Hospital, Liverpool Hospital, Juravinski Hospital, Union for International Cancer Control, Princess Margaret Cancer Centre, Terry Fox Research Institute, Royal Alexandra Hospital, International Network for Cancer Treatment and Research, Kijabe Hospital, National Cancer Institute, Institute for Clinical Evaluative Sciences, Cross Cancer Institute, Canadian Cancer Trials Group, Odette Cancer Centre, Hamilton Health Sciences, McMaster University
OpenAlex ID: A5024378366
Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial
2013 · Dan Stark, Matthew Nankivell, et al. · The Lancet Oncology · 137
An Endodermal Sinus Tumor Diagnosed in Pregnancy: Case Report and Review of the Literature
1999 · L. Elit, A. Bocking, et al. · Gynecologic Oncology · 126
Quality of life and psychosexual adjustment after prophylactic oophorectomy for a family history of ovarian cancer
2001 · L. Elit, M.J. Esplen, et al. · Familial Cancer · 120
Impact of Wait Times on Survival for Women With Uterine Cancer
2013 · Lorraine M. Elit, Erin M. O'Leary, et al. · Journal of Clinical Oncology · 115
PDF
The impact of prophylactic salpingo‐oophorectomy on quality of life and psychological distress in women with a BRCA mutation
2011 · Amy Finch, Kelly A. Metcalfe, et al. · Psycho-Oncology · 93
Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer—NCIC IND 160
2006 · A. M. Oza, L. Elit, et al. · Journal of Clinical Oncology · 89
Outcomes in Surgery for Ovarian Cancer
2002 · L. Elit, S.J. Bondy, et al. · Gynecologic Oncology · 89
Follow-Up for Women after Treatment for Cervical Cancer
2010 · L. Elit, A.W. Fyles, et al. · Current Oncology · 87
PDF
Delayed delivery of second twin: report of four cases and review of the literature.
1992 · B K Wittmann, D Farquharson, et al. · PubMed · 73
Splenic cyst carcinoma presenting in pregnancy
1989 · L. Elit, B. Aylward · American Journal of Hematology · 54
A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b
2008 · A. M. Oza, L. Elit, et al. · Journal of Clinical Oncology · 53
Phase II study of oral ridaforolimus in patients with metastatic and/or locally advanced recurrent endometrial cancer: NCIC CTG IND 192.
2011 · H. Mackay, S. Welch, et al. · Journal of Clinical Oncology · 40
Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective.
1997 · L M Elit, A Gafni, et al. · Journal of Clinical Oncology · 39
It's a choice to move forward: women's perceptions about treatment decision making in recurrent ovarian cancer
2009 · L. Elit, C. Charles, et al. · Psycho-Oncology · 37
Optimal management for surgically Stage 1 serous cancer of the uterus
2003 · L Elit · Gynecologic Oncology · 37
Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review
2007 · H.W. Hirte, J.E. Strychowsky, et al. · International Journal of Gynecological Cancer · 32
High-Dose Methotrexate for Gestational Trophoblastic Disease
1994 · L. Elit, A. Covens, et al. · Gynecologic Oncology · 32
Phase II study of sorafenib (BAY 43–9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: A PMH phase II consortium trial
2006 · S. Welch, H. Hirte, et al. · Journal of Clinical Oncology · 26
Sorafenib (SOR) in patients (pts) with advanced/recurrent uterine carcinoma (UCA) or carcinosarcoma (CS): A phase II trial of the University of Chicago, PMH, and California Phase II Consortia
2008 · H. S. Nimeiri, A. M. Oza, et al. · Journal of Clinical Oncology · 21
Endometrial cancer presentation is associated with social determinants of health in a public healthcare system: A population-based cohort study
2020 · Limor Helpman, Greg R. Pond, et al. · Gynecologic Oncology · 20
Breast and ovarian cancer risk perception after prophylactic salpingo‐oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene
2009 · A Finch, K Metcalfe, et al. · Clinical Genetics · 20
Phase II study of erlotinib (OSI 774) in women with recurrent or metastatic endometrial cancer: NCIC CTG IND-148
2004 · K. V. Jasas, A. Fyles, et al. · Journal of Clinical Oncology · 20
A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) as second-line therapy in patients with recurrent platinum-sensitive ovarian cancer.
2013 · Isabelle Ray-Coquard, Paul Haluska, et al. · Journal of Clinical Oncology · 18
Effect of Positron Emission Tomography Imaging in Women With Locally Advanced Cervical Cancer
2018 · Lorraine M. Elit, Anthony W. Fyles, et al. · JAMA Network Open · 15
PDF
How oncologists communicate information to women with recurrent ovarian cancer in the context of treatment decision making in the medical encounter
2013 · Lorraine M. Elit, Cathy Charles, et al. · Health Expectations · 15
PDF
Works count: 68
Citation count: 1,568
H-index: 20
I10-index: 31
Year
Topic
Type